Literature DB >> 22459675

Activity enhances dopaminergic long-duration response in Parkinson disease.

Un Jung Kang1, Peggy Auinger.   

Abstract

OBJECTIVE: We tested the hypothesis that dopamine-dependent motor learning mechanism underlies the long-duration response to levodopa in Parkinson disease (PD) based on our studies in a mouse model. By data-mining the motor task performance in dominant and nondominant hands of the subjects in a double-blind randomized trial of levodopa therapy, the effects of activity and dopamine therapy were examined.
METHODS: We data-mined the Earlier versus Later Levodopa Therapy in Parkinson's Disease (ELLDOPA) study published in 2005 and performed statistical analysis comparing the effects of levodopa and dominance of handedness over 42 weeks.
RESULTS: The mean change in finger-tapping counts from baseline before the initiation of therapy to predose at 9 weeks and 40 weeks increased more in the dominant compared to nondominant hand in levodopa-treated subjects in a dose-dependent fashion. There was no significant difference in dominant vs nondominant hands in the placebo group. The short-duration response assessed by the difference of postdose performance compared to predose performance at the same visit did not show any significant difference between dominant vs nondominant hands.
CONCLUSIONS: Active use of the dominant hand and dopamine replacement therapy produces synergistic effect on long-lasting motor task performance during "off" medication state. Such effect was confined to dopamine-responsive symptoms and not seen in dopamine-resistant symptoms such as gait and balance. We propose that long-lasting motor learning facilitated by activity and dopamine is a form of disease modification that is often seen in trials of medications that have symptomatic effects.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22459675      PMCID: PMC3466780          DOI: 10.1212/WNL.0b013e31824f8056

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  10 in total

1.  Pharmacodynamics of the long-duration response to levodopa in PD.

Authors:  M Zappia; D Bosco; M Plastino; G Nicoletti; D Branca; R L Oliveri; U Aguglia; A Gambardella; A Quattrone
Journal:  Neurology       Date:  1999-08-11       Impact factor: 9.910

2.  Dopamine-dependent motor learning: insight into levodopa's long-duration response.

Authors:  Jeff A Beeler; Zhen Fang Huang Cao; Mazen A Kheirbek; Yunmin Ding; Jessica Koranda; Mari Murakami; Un Jung Kang; Xiaoxi Zhuang
Journal:  Ann Neurol       Date:  2010-05       Impact factor: 10.422

Review 3.  Short-term and long-term plasticity at corticostriatal synapses: implications for learning and memory.

Authors:  Massimiliano Di Filippo; Barbara Picconi; Michela Tantucci; Veronica Ghiglieri; Vincenza Bagetta; Carmelo Sgobio; Alessandro Tozzi; Lucilla Parnetti; Paolo Calabresi
Journal:  Behav Brain Res       Date:  2008-10-02       Impact factor: 3.332

4.  Short- and long-duration responses to levodopa during the first year of levodopa therapy.

Authors:  J G Nutt; J H Carter; L Van Houten; W R Woodward
Journal:  Ann Neurol       Date:  1997-09       Impact factor: 10.422

5.  Levodopa and the progression of Parkinson's disease.

Authors:  Stanley Fahn; David Oakes; Ira Shoulson; Karl Kieburtz; Alice Rudolph; Anthony Lang; C Warren Olanow; Caroline Tanner; Kenneth Marek
Journal:  N Engl J Med       Date:  2004-12-09       Impact factor: 91.245

Review 6.  Presymptomatic compensation in Parkinson's disease is not dopamine-mediated.

Authors:  Erwan Bezard; Christian E Gross; Jonathan M Brotchie
Journal:  Trends Neurosci       Date:  2003-04       Impact factor: 13.837

7.  L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects.

Authors:  M D Muenter; G M Tyce
Journal:  Mayo Clin Proc       Date:  1971-04       Impact factor: 7.616

8.  A double-blind, delayed-start trial of rasagiline in Parkinson's disease.

Authors:  C Warren Olanow; Olivier Rascol; Robert Hauser; Paul D Feigin; Joseph Jankovic; Anthony Lang; William Langston; Eldad Melamed; Werner Poewe; Fabrizio Stocchi; Eduardo Tolosa
Journal:  N Engl J Med       Date:  2009-09-24       Impact factor: 91.245

9.  Dichotomous dopaminergic control of striatal synaptic plasticity.

Authors:  Weixing Shen; Marc Flajolet; Paul Greengard; D James Surmeier
Journal:  Science       Date:  2008-08-08       Impact factor: 47.728

10.  Evolution of the response to levodopa during the first 4 years of therapy.

Authors:  John G Nutt; Julie H Carter; Eric S Lea; Gary J Sexton
Journal:  Ann Neurol       Date:  2002-06       Impact factor: 10.422

  10 in total
  11 in total

1.  Paradoxical effect of dopamine medication on cognition in Parkinson's disease: relationship to side of motor onset.

Authors:  Brenda Hanna-Pladdy; Rajesh Pahwa; Kelly E Lyons
Journal:  J Int Neuropsychol Soc       Date:  2015-04-29       Impact factor: 2.892

2.  Chronic Nicotine Mitigates Aberrant Inhibitory Motor Learning Induced by Motor Experience under Dopamine Deficiency.

Authors:  Jessica L Koranda; Anne C Krok; Jian Xu; Anis Contractor; Daniel S McGehee; Jeff A Beeler; Xiaoxi Zhuang
Journal:  J Neurosci       Date:  2016-05-11       Impact factor: 6.167

3.  Motor phenotype classification in moderate to advanced PD in BioFIND study.

Authors:  Lan Luo; Howard Andrews; Roy N Alcalay; Fernanda Carvalho Poyraz; Amelia K Boehme; Jennifer G Goldman; Tao Xie; Paul Tuite; Claire Henchcliffe; Penelope Hogarth; Amy W Amara; Samuel Frank; Margaret Sutherland; Catherine Kopil; Anna Naito; Un Jung Kang
Journal:  Parkinsonism Relat Disord       Date:  2019-06-23       Impact factor: 4.891

Review 4.  The role of neuroplasticity in dopaminergic therapy for Parkinson disease.

Authors:  Xiaoxi Zhuang; Pietro Mazzoni; Un Jung Kang
Journal:  Nat Rev Neurol       Date:  2013-04-16       Impact factor: 42.937

5.  Study in Parkinson disease of exercise (SPARX): translating high-intensity exercise from animals to humans.

Authors:  Charity G Moore; Margaret Schenkman; Wendy M Kohrt; Anthony Delitto; Deborah A Hall; Daniel Corcos
Journal:  Contemp Clin Trials       Date:  2013-06-14       Impact factor: 2.226

Review 6.  Adaptive changes in striatal projection neurons explain the long duration response and the emergence of dyskinesias in patients with Parkinson's disease.

Authors:  Björn Falkenburger; Theodoros Kalliakoudas; Heinz Reichmann
Journal:  J Neural Transm (Vienna)       Date:  2022-05-10       Impact factor: 3.850

7.  Changes in Striatal Medium Spiny Neuron Morphology Resulting from Dopamine Depletion Are Reversible.

Authors:  Victoria Sofie Witzig; Daniel Komnig; Björn H Falkenburger
Journal:  Cells       Date:  2020-11-09       Impact factor: 6.600

8.  The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort.

Authors:  Un Jung Kang; Jennifer G Goldman; Roy N Alcalay; Tao Xie; Paul Tuite; Claire Henchcliffe; Penelope Hogarth; Amy W Amara; Samuel Frank; Alice Rudolph; Cynthia Casaceli; Howard Andrews; Katrina Gwinn; Margaret Sutherland; Catherine Kopil; Lona Vincent; Mark Frasier
Journal:  Mov Disord       Date:  2016-04-26       Impact factor: 10.338

Review 9.  Exercise-Induced Neuroprotection of the Nigrostriatal Dopamine System in Parkinson's Disease.

Authors:  Lijuan Hou; Wei Chen; Xiaoli Liu; Decai Qiao; Fu-Ming Zhou
Journal:  Front Aging Neurosci       Date:  2017-11-03       Impact factor: 5.750

10.  Unraveling connectivity changes due to dopaminergic therapy in chronically treated Parkinson's disease patients.

Authors:  Tommaso Ballarini; Filip Růžička; Ondrej Bezdicek; Evžen Růžička; Jan Roth; Arno Villringer; Josef Vymazal; Karsten Mueller; Matthias L Schroeter; Robert Jech
Journal:  Sci Rep       Date:  2018-09-25       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.